
InflaRx N.V. IFRX
$ 1.05
-4.55%
InflaRx N.V. Interest Expense | IFRX
Interest expense is the amount of interest a company is obligated to pay to creditors for using debt financing (bank loans, bonds, leasing, etc.) during the reporting period.Includes:
- Interest on bank loans
- Interest on corporate bonds
- Interest on leases
- Interest on credit lines and overdrafts
High interest expenses indicate a high debt burden — the company may be vulnerable to rising rates or declining revenue.
Low interest expenses with high profits are a sign of financial stability.
Annual Interest Expense InflaRx N.V.
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2.69 K | 885 | 16.5 K | 23.3 K | 10.7 K | 18.7 K | - | - | - | - | - | - | - | - | - |
Annual performance
Select metrics to display
All numbers in EUR currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 23.3 K | 885 | 12.1 K |
Quarterly Interest Expense InflaRx N.V.
| 2025-Q4 | 2025-Q2 | 2024-Q4 | 2024-Q2 | 2023-Q4 | 2023-Q2 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2.69 K | - | 885 | - | 16.5 K | 363 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Quarterly performance
Select metrics to display
All numbers in EUR currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 16.5 K | 363 | 5.12 K |
Interest Expense of other stocks in the Biotechnology industry
| Issuer | Interest Expense | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Sesen Bio
SESN
|
296 K | - | 7.29 % | $ 127 M | ||
|
Windtree Therapeutics
WINT
|
-408 K | - | - | $ 26.8 M | ||
|
Trean Insurance Group
TIG
|
3.27 M | - | - | $ 316 M | ||
|
SQZ Biotechnologies Company
SQZ
|
-3 K | - | 57.95 % | $ 12.8 M | ||
|
MEI Pharma
MEIP
|
-16 K | - | 10.43 % | $ 20.5 M | ||
|
Palatin Technologies
PTN
|
290 K | - | - | $ 13 M | ||
|
Brickell Biotech
BBI
|
5 K | - | -5.38 % | $ 6.06 M | ||
|
Applied Therapeutics
APLT
|
-77 K | - | - | $ 8.42 M | ||
|
Merus N.V.
MRUS
|
1.06 M | - | - | $ 5.78 B | ||
|
Annexon
ANNX
|
57 K | $ 3.11 | -8.94 % | $ 482 M | ||
|
Galapagos NV
GLPG
|
1.03 M | - | - | $ 1.83 B | ||
|
Cyclacel Pharmaceuticals
CYCCP
|
31 K | - | -4.36 % | $ 27 M | ||
|
Avenue Therapeutics
ATXI
|
294 K | - | -52.27 % | $ 4.45 M | ||
|
Galmed Pharmaceuticals Ltd.
GLMD
|
741 K | $ 4.63 | 21.05 % | $ 20 M | ||
|
Achieve Life Sciences
ACHV
|
-36 K | $ 6.78 | 0.89 % | $ 296 M | ||
|
Leap Therapeutics
LPTX
|
54 K | - | 368.57 % | $ 41.9 M | ||
|
Lumos Pharma
LUMO
|
683 K | - | - | $ 35.3 M | ||
|
Axcella Health
AXLA
|
3.02 M | - | -16.42 % | $ 249 M | ||
|
Metacrine
MTCR
|
1.2 M | - | - | $ 24.2 M | ||
|
Myovant Sciences Ltd.
MYOV
|
14 M | - | -0.04 % | $ 2.62 B | ||
|
Idera Pharmaceuticals
IDRA
|
7 K | - | -23.04 % | $ 26.6 M | ||
|
Akero Therapeutics
AKRO
|
4.67 M | - | - | $ 3.67 B | ||
|
Verona Pharma plc
VRNA
|
340 K | - | - | $ 69.7 B | ||
|
Atreca
BCEL
|
3 K | - | -11.76 % | $ 5.79 M | ||
|
Guardion Health Sciences
GHSI
|
7.27 K | - | -0.31 % | $ 3.64 M | ||
|
Opiant Pharmaceuticals
OPNT
|
2.13 M | - | - | $ 109 M | ||
|
Akouos
AKUS
|
-1.72 M | - | 0.23 % | $ 488 M | ||
|
ImmunoGen
IMGN
|
-994 K | - | - | $ 7.92 B | ||
|
Vascular Biogenics Ltd.
VBLT
|
179 K | - | -8.77 % | $ 12.4 M | ||
|
Cidara Therapeutics
CDTX
|
5.81 M | - | - | $ 1.41 B | ||
|
Iterum Therapeutics
ITRM
|
-47 K | - | - | $ 591 K | ||
|
Virpax Pharmaceuticals
VRPX
|
12.7 K | - | -45.12 % | $ 2.85 M | ||
|
Navidea Biopharmaceuticals
NAVB
|
-27.9 K | - | -2.99 % | $ 2.47 M | ||
|
Stealth BioTherapeutics Corp
MITO
|
1.24 M | - | - | $ 23.9 M | ||
|
OncoSec Medical Incorporated
ONCS
|
20.9 K | - | 31.87 % | $ 1.61 M |